Michael Silverberg to Anti-HIV Agents
This is a "connection" page, showing publications Michael Silverberg has written about Anti-HIV Agents.
Connection Strength
6.962
-
Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial. J Acquir Immune Defic Syndr. 2024 Apr 01; 95(4):362-369.
Score: 0.836
-
Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
Score: 0.817
-
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
Score: 0.480
-
The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
Score: 0.467
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.380
-
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
Score: 0.370
-
Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. Sex Transm Dis. 2010 Jan; 37(1):53-8.
Score: 0.312
-
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009 Mar 03; 150(5):301-13.
Score: 0.294
-
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022 06; 9(6):e404-e413.
Score: 0.184
-
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
Score: 0.181
-
Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. Clin Infect Dis. 2020 12 17; 71(10):2710-2712.
Score: 0.166
-
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clin Trials. 2018 10; 19(5):177-187.
Score: 0.144
-
A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):548-553.
Score: 0.132
-
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):568-576.
Score: 0.132
-
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
Score: 0.132
-
Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):197-204.
Score: 0.124
-
Disparities in Uptake of HIV Preexposure Prophylaxis in a Large Integrated Health Care System. Am J Public Health. 2016 10; 106(10):e2-3.
Score: 0.124
-
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis. 2016 11 01; 63(9):1160-1167.
Score: 0.123
-
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):50-8.
Score: 0.116
-
Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. HIV Med. 2015 Oct; 16(9):572-7.
Score: 0.113
-
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis. 2013 Apr; 56(8):1174-82.
Score: 0.096
-
Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
Score: 0.092
-
Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
Score: 0.091
-
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
Score: 0.089
-
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901.
Score: 0.088
-
Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
Score: 0.087
-
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
Score: 0.078
-
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90.
Score: 0.077
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.072
-
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
Score: 0.069
-
Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
Score: 0.069
-
The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):232-241.
Score: 0.054
-
Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Res Ther. 2024 Aug 07; 21(1):52.
Score: 0.054
-
Life and Disability Insurance for People with or at Risk of HIV: Aligning Policy with Evidence. J Insur Med. 2024 Jul 01; 51(1):25-28.
Score: 0.053
-
Care interruptions and mortality among adults in Europe and North America. AIDS. 2024 Aug 01; 38(10):1533-1542.
Score: 0.053
-
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
Score: 0.044
-
Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):663-670.
Score: 0.043
-
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
Score: 0.042
-
Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study. Lancet HIV. 2019 10; 6(10):e688-e695.
Score: 0.038
-
Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. 2013 Aug; 27(8):442-9.
Score: 0.025
-
HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
Score: 0.021